IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Bristol Myers ends Cellares partnership

Bristol Myers Squibb has ended its manufacturing partnership with Cellares after determining the startup platform could not scale Breyanzi production. Cellares plans to cut one hundred jobs following the lost deal.

Xurve View
Insights:
FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo

Bristol Myers Squibb cancelled its partnership with cell therapy startup Cellares after determining the firm's manufacturing platform could not scale Breyanzi production. The termination triggered 100 layoffs at the startup's California facility. The collapsed agreement ends a 2024 pact worth up to $380M.
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.